Hyperkalemia
Methodology & AI Transparency ⓘ
Hyperkalemia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Hyperkalemia (ICD-10-CM E87.5), Chronic Kidney Disease & Electrolytes protocols prioritize serial eGFR (creatinine in Hyperkalemia (E87.5: + cystatin C)) paired with baseline and interval Serum Potassium, Bicarbonate in Hyperkalemia (E87.5: & Phosphorus) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code E87.5 categorizes Hyperkalemia under Chronic Kidney Disease & Electrolytes.
- 3 Typical cash cost range: Clinicians assessing Hyperkalemia focus on glomerular capillary hyperfiltration in Hyperkalemia (E87.5: barotrauma) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Hyperkalemia monitoring tracks Serum Potassium, Bicarbonate in Hyperkalemia (E87.5: & Phosphorus) toward K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.5).
Ask our AI Specialists anything about Hyperkalemia
What Is Hyperkalemia?
For patients presenting with Hyperkalemia (ICD-10-CM E87.5), Chronic Kidney Disease & Electrolytes protocols prioritize serial eGFR (creatinine in Hyperkalemia (E87.5: + cystatin C)) paired with baseline and interval Serum Potassium, Bicarbonate in Hyperkalemia (E87.5: & Phosphorus) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
In Hyperkalemia (E87.5), physiological disruption stems from glomerular capillary hyperfiltration in Hyperkalemia (E87.5: barotrauma), informing Chronic Kidney Disease & Electrolytes protocols that track eGFR (Creatinine + in Hyperkalemia (E87.5: Cystatin C)) (>= 90 mL/min/1.73m2 (E87.5)).
Common Symptoms & Clinical Signs
- • Presentation of Hyperkalemia (E87.5): asymptomatic decline in in Hyperkalemia (E87.5: eGFR or persistent)
- • Secondary Hyperkalemia clinical sign: fluid retention in in Hyperkalemia (E87.5: ankles, hands, or)
- • Symptom flares in Hyperkalemia correlating with Serum Potassium, Bicarbonate in Hyperkalemia (E87.5: & Phosphorus) deviation outside K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.5)
- • Functional kidney & renal impact requiring serial eGFR (creatinine in Hyperkalemia (E87.5: + cystatin C)) evaluation (E87.5)
Hyperkalemia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E87.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Hyperkalemia (E87.5: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Hyperkalemia (E87.5: Cystatin C)) | >= 90 mL/min/1.73m2 (E87.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Hyperkalemia (E87.5: (uACR)) | < 15 mg/g (< 30 mg/g normal) (E87.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hyperkalemia
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Sodium Zirconium Cyclosilicate Lokelma • RxCUI 2047642 | FDA Prescription Therapeutic Agent | 87% | $27.5413 | $ 185.00 /mo |
| Patiromer Veltassa • RxCUI 1716209 | Potassium Binder | 92% | $34.0169 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hyperkalemia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Modified-release nicotinamide for the treatment of hyperphosphataemia in: What a 358-Participant Study Found NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2023-03-31 • Phase III Randomized Trial | N = 358 | 93/100 | PMID 35751625 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of patiromer for hyperkalemia: a randomized, compared against Patiromer can improve hyperkalemia by lowering sK-level and can suppress the recurrence of hyperkalemia with continued administration, and is safe and easy-to-use for a wide range of patients. Clinical and experimental nephrology • 2025-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39976633 ↗ |
| Can This Approach Help? Inside the Latest Research on Pre-hemodialysis exercise training improves systemic aerobic capacity and The preHD-ET for 36 weeks improves systemic aerobic capacity in ESRD patients. Life sciences • 2026-07-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42009192 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunotherapy-based combination associated score as a robust predictor for This study has collectively developed an immunotherapy-based combination associated score, pinpointed effective biomarkers for prognostic and responsiveness of kidney cancer patients to immunotherapy-based combinations, and... Computers in biology and medicine • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39341105 ↗ |
| Can This Approach Help? Inside the Latest Research on Modest efficacy of nivolumab plus ipilimumab in patients with papillary kidney Nivolumab plus ipilimumab had modest efficacy for papillary kidney cell carcinoma compared with that for clear cell kidney cell carcinoma. Japanese journal of clinical oncology • 2021-04-01 • Phase III Randomized Trial | N = 30 | 82/100 | PMID 33212488 ↗ |
Hyperkalemia Patient Community & “People Like Me” Threads
Filter Hyperkalemia community threads and patient logs by age, biological sex, dosage, and treatment duration.